FinDogFinDog
Monday, October 12, 2026Closing data · 4:00 PM ET
English
Log in

ILMN

Illumina, Inc.NASDAQ · Life Sciences Tools & Services · Health Care
Previous close
276.67
Change
−1.50 / −0.54%
FinDog View
Bullish
52-Week Range ?
88.00 – 309.35
P/E (TTM) ?
50.9
Forward P/E ?
42.1
Based on consensus earnings for the next 12 months
Market Cap
$42.0B
1M
+34.01%
S&P 500 +1.81% over same period
Volume / Avg Volume
1.6M / 3.0M
0.56× average
Latest earnings analysisFY2026 Q2Reported 2026-07-30

Illumina Q2 FY2026: revenue up 9.5%, EPS beats, guidance raised

Illumina's fiscal Q2 2026 revenue rose 9.5% to $1.159 billion and non-GAAP EPS of $1.31 beat the $1.2507 consensus, prompting management to raise full-year revenue and EPS guidance. The catch is that GAAP net income fell to $207 million from $235 million, because last year's quarter carried a large investment gain. Read the revenue and EPS notes for the quality of the beat, then the guidance section for what management now promises.

Read the full analysis →
Revenue$1.16BYoY +9.40%
EPS (non-GAAP)$1.31Beatest. $1.25
Next-quarter revenue guidance$4.62B ±0.43%YoY +298.60%
Next-day move0.00%

Price History

Closing price · USD1M6M1Y5Y
2002252502753002026-092026-092026-092026-102026-10

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 50.01M6M1Y5Y
35404550552026-092026-092026-092026-102026-10

Recent Earnings

Click to read the FinDog analysis
PeriodReportedRevenueEPS Actual / Est.Next-Day MoveAnalysis

Next Earnings

Date and consensus from the earnings calendar; the analysis is generated automatically after the releaseEarnings Calendar →
Report date
2027-02-03
in 113 days · After hours
Consensus EPS
$1.57
Last quarter EPS $1.31
Avg. next-day move over the last 6 reports
±8.2%

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data
Valuation
P/E is at percentile 98 of its 5-year rangeExpensive
5-year range 12.2 – 46.2 · Median 27.4
Last 4 quarters: $542M in buybacks + $0 in dividends, 1.29% of market cap combined
P/E (TTM)
50.9
P/B
14.8
P/S
9.4
PEG
3.82
Earnings Reaction
Over the last 6 reports, the stock moved ±8.2% on average on the first trading day after, rising 3 times
Most recent 0.00%
Insider Trading
View all →
Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
No open-market buys or sells by officers or directors in the last 90 days.
Multi-Quarter Financial Trends
View all quarters →
Last 12 quarters · As reported by the company
QuarterRevenue ($B)YoYGross MarginOperating Income ($B)Net Income ($B)Free Cash Flow ($B)EPS
FY2026 Q21.16+9.4%66.4%0.250.210.161.35
FY2026 Q11.09+4.8%66.1%0.210.130.250.87
FY2025 Q41.16+5.0%65.5%0.200.330.272.16
FY2025 Q31.08+0.4%67.6%0.230.150.250.98
FY2025 Q21.06−4.8%65.6%0.210.240.201.49
FY2025 Q11.04−3.3%65.6%0.160.130.210.82
FY2024 Q41.10−1.6%65.9%0.170.190.341.16
FY2024 Q31.08−3.5%69.0%0.740.710.284.42
FY2024 Q21.11−5.4%64.8%-1.64-1.990.05-12.48
FY2024 Q11.08−1.0%62.0%-0.11-0.130.04-0.79
FY2023 Q41.12+3.5%60.0%-0.16-0.180.17-1.11
FY2023 Q31.12+0.4%61.1%-0.75-0.750.09-4.77

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →
TickerCompanyMarket CapP/ERevenue YoYGross Margin1MView